Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease
Authors' conclusion
Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.
Study context
- Population
- Patients aged ≥45 years at ≥6 months after coronary event (RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, HELIUS)24% women
- Participants
- 3,230 patients
- Comparison
- Maximal risk factor treatment vs current treatment
- Outcome
- Estimated 10-year and lifetime risk of recurrent atherosclerotic CV events (SMART-REACH score) and gain in event-free years
- Follow-up
- 10-year and lifetime
Methodological detailsrisk modelling study, pooled data from six studies, SMART-REACH score
- Risk modelling study
- Pooled data from six studies
- SMART-REACH score
Pooled result
As reported in the abstract
Estimated risk of recurrent atherosclerotic CV events (SMART-REACH score) · median 1.1 years (IQR 1.0-1.8) after index event
- 10-year risk with current treatment, median (IQR)
- 20% (15-27%)
- Lifetime risk with current treatment, median (IQR)
- 54% (47-63%)
- 10-year risk with maximal treatment, median (IQR)
- 6% (4-8%)
- Lifetime risk with maximal treatment, median (IQR)
- 20% (15-27%)
- Gain in atherosclerotic CVD event-free years with maximal treatment, median (IQR)
- 7.3 (5.4-10.4)
Further pooled results
Risk factor control
- Used conventional medication
- 70%
- ≥1 drug-modifiable risk factor not on target
- 82%
- ≥1 lifestyle-related risk factor not on target
- 91%
Original publication
Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. Eur J Prev Cardiol. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →